Shihuituan, a China-based community group buying platform also known as Nice Tuan, has raised $196 million in the third tranche of a Series C round led by Alibaba Group and Jeneration Capital.
CDH Investments has reached the first close of RMB1.5 billion ($228 million) on a data center industry fund. Part of the Chinese GP's mezzanine strategy, the vehicle has a full target of RMB2 billion.
Private equity investors are willing to reconsider their options regarding the location of their fund management companies even as they remain wedded to the Cayman Islands as a domicile for funds, the AVCJ Forum heard.
Online lending and wealth management platform Lufax raised $2.36 billion in the largest US IPO by a PE-backed Chinese company so far this year but endured a difficult first day of trading.
Lufax, a Chinese online lending and wealth management platform valued at $39.4 billion following its most recent private funding round, has filed for an IPO in the US.
Canadian Solar, a NASDAQ-listed solar power company, has raised RMB1.78 billion ($260 million) to carve out certain China-based assets ahead of a local IPO.
Virogin Biotech, a drug developer based in China and Canada, has received $62 million in Series C funding led by CDH Invesmtents and a subsidiary of State Development and Investment Corporation (SDIC).
Valuations are rising in China’s data center industry as speculative real estate-style investors flood the market. Experienced players are willing to spend more time building scale
Chinese commercial rocket developer i-Space - also known as Interstellar Glory Space - has raised a RMB1.2 billion ($173 million) Series B round led by State-owned Beijing Financial Street Capital Operation Center.
Distress-focused investors warned that persistent economic uncertainty is making it difficult to act on opportunities even as companies run into trouble because of the coronavirus pandemic.
CDH Investment has led a RMB200 million ($28 million) Series B round for Guangzhou-based precision diagnosis and gene sequencing company Vision Medicals.
Shihuituan, a China-based community group buying platform also known as Nice Tuan, has raised $80 million in the second tranche of a Series C round led by CDH Investments.
BlueCity Holdings, the VC-backed holding company for Chinese gay dating platform Blued, traded strongly after raising $84.8 million through a NASDSAQ IPO.
There has been little VC investment in Chinese LGBTQ social platforms since 2017 due to regulatory concerns. Will gay dating site Blued’s US IPO reignite interest in the space?
Chinese drug developer SinocellTech nearly trebled in value on its first day of trading on China's Science and Technology Innovation Board (Star Market) following a RMB1.28 billion ($181 million) IPO.
BlueCity Holdings, the company behind Chinese gay dating platform Blued, has filed an application to list on NASDAQ, which would provide a liquidity event for several PE and VC investors.
China’s local currency mezzanine capital space is underpenetrated, underpopulated and different to comparable strategies elsewhere. A handful of domestic GPs have begun to get traction. Will others follow?
Lehe Food, a China-based distributor of fresh food and ingredients, has secured RMB400 million ($56 million) in Series C funding led by Dragon Ball Capital and CDH Investments. Existing backer Hezhi Investment re-upped.
CDH Investments has closed its fifth China mezzanine fund at RMB8 billion ($1.1 billion). It is the largest vehicle of its kind ever raised solely for deployment in the country.
Telaidian’s recent Series A round underlines the opportunities in China’s electric vehicle charging space. While growth seems certain, some industry dynamics have yet to play out
A recent commitment by China’s CDH Investments to Wow Tech underlines how sensual health products such as vibrators are moving from the margins to the mainstream, globally and in Asia
CDH Investments has closed its sixth flagship US dollar-denominated fund with $1.5 billion in commitments. The initial target was $2.5 billion.
CDH Investments and Shenzhen Capital Group have co-led a $50 million Series B round for GenFleet Therapeutics, a Chinese drug developer.
Telaidian, which claims to operate China's largest electric vehicle (EV) charging network, has raised RMB1.35 billion ($190 million) in Series A funding.